Recent Updates
Recently added Catalysts
RCEL Positive Sentiment Score: 80/100

AVITA Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference

Key Takeaway: AVITA Medical announced that CEO Cary Vance will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The event will include a live audio webcast, which will be accessible via the company's website. AVITA Medical is known for its RECELL System, which accelerates wound healing by using a patient's own skin and is FDA-approved for treating burns and trauma wounds. The company's solutions aim to improve clinical outcomes in various markets, including European, Australian, and Japanese markets.

Market Sentiment Analysis

POSITIVE FACTORS

  • AVITA Medical will present at a well-regarded industry conference.
  • The RECELL System offers innovative solutions for wound healing.
  • Cary Vance, the CEO, will represent the company, showcasing leadership.

Full Press Release Details

VALENCIA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced that Cary Vance, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 5:15 p.m. Pacific Time.
A live audio webcast of the presentation will be accessible under the Events & Presentations section of AVITA Medical's website at https://ir.avitamedical.com/events-and-presentations. A replay of the webcast will be available following the conclusion of the event.
About AVITA Medical, Inc.
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the rights to manufacture and exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications, including thermal burn and trauma wounds, with regulatory clearances in Europe, and excluding RECELL GO, in Australia and Japan.
To learn more, visit www.avitamedical.com.
Investor & Media Contact:
Phone +1-805 341 1571
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.

Tags

Frequently Asked Questions

When will AVITA Medical present at the J.P. Morgan Conference?

AVITA Medical will present on January 14, 2026, at 5:15 p.m. PT.

Where can I watch the AVITA Medical presentation?

The presentation will be streamed live on AVITA's website.

What is the RECELL System used for?

The RECELL System is used for treating thermal burn and trauma wounds.

What products does AVITA Medical manufacture?

AVITA manufactures the RECELL System, PermeaDerm®, and Cohealyx™.

Is RECELL approved for use outside the U.S.?

Yes, RECELL is approved for various applications in multiple international markets.

Last updated: Dec 18, 2025